It has been reported that HDAC inhibitors can alter the subgroup of CD4 and CD8 tumor-infiltrating T cells in colorectal cancer (Blaszczak et al., 2021) and enhance the effectiveness of immunotherapy in multiple myeloma (Hirano et al., 2021). This evidence concerns the gene CD8A and colorectal cancer.